Shares of PVR INOX fell 2.5% to the day’s low of Rs 1,000 on the BSE on Tuesday, even as the company returned to profitability in the March quarter, reporting a consolidated net profit of Rs 187 crore versus a loss of Rs 125 crore in the same period last year.
The multiplex operator said strong performance from blockbuster titles, including Dhurandhar – The Revenge, Border 2 and Project Hail Mary, supported the earnings recovery.
With Tuesday’s decline, the stock is down 6% in two sessions.
Revenue from operations for Q4FY26 rose 26% year-on-year to Rs 1,547 crore, up from Rs 1,230 crore reported in the corresponding quarter of the previous financial year. On a sequential basis, profit after tax rose 95% to Rs 187 crore from Rs 96 crore in Q3FY26, even as revenue declined 16% quarter-on-quarter to Rs 1,850 crore in the October–December period.
Advertisement
During the quarter, the company recorded 31 million admissions, reflecting a 2% year-on-year increase. Average ticket price (ATP) stood at Rs 315, up 22% from a year ago, while spend per head (SPH) rose 32% year-on-year to Rs 165.
Live Events
PVR Inox share price: Should you buy, sell, or hold?
Nuvama Institutional Equities has maintained its “Buy” rating on PVR INOX, with a revised target price of Rs 1,620 from Rs 1,605 earlier, implying 58% upside potential. The brokerage expects FY27 to remain strong, driven by a healthy Bollywood and regional film pipeline along with a steady slate from Hollywood. It has retained its earnings estimates and noted that at the current market price, the stock trades at 13x and 11x FY27E and FY28E earnings, respectively. Nuvama noted that the company’s net debt has declined 90% since the 2023 merger, marking its lowest level since the consolidation. Elara Capital has maintained its “Buy” rating on PVR INOX with a target price of Rs 1,300, implying an upside potential of 27%. The brokerage said occupancy levels could sustain in the 25-27% range, supported by a stronger near-term content pipeline that includes titles such as Drishyam 3, Star Wars: The Mandalorian and Grogu, Ramayana Part 1, King, Avengers: Doomsday, Dune: Part 3, Toy Story 5, Toxic and Jailer 2. Elara Capital, however, expects growth in ATP and SPH to moderate after the normalisation seen in FY26. It added that the company’s FOCO and asset-light expansion strategy is likely to support lower capital expenditure intensity and improve free cash flow generation going ahead. Motilal Oswal Financial Services has maintained a “Neutral” rating on PVR INOX with a target price of Rs 1,125, indicating a potential upside of 10%. The brokerage said a recovery in Hollywood box office collections, along with a strong content pipeline across multiple languages, is expected to support the company, particularly given its higher exposure to premium screening formats.
Motilal Oswal also noted that PVR INOX has made significant progress in controlling operating costs, optimising capital expenditure and reducing debt on its balance sheet. However, it cautioned that the business remains highly sensitive to occupancy levels. While management remains optimistic about the CY26 content slate, the brokerage warned that even a 200-300 basis point decline in occupancy could materially hurt screen-level economics and EBITDA performance, creating downside risks to its current estimates.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Ladies and gentlemen, greetings, and welcome to the Quantum Computing, Inc. First Quarter 2026 Shareholder Update Call. [Operator Instructions] It is now my pleasure to introduce your host, John Nesbett with IMS Investor Relations.
John Nesbett
Advertisement
Thank you, and I want to welcome everyone to the Quantum Computing, Inc. First Quarter 2026 Shareholder Update Call. Before we begin, please note that today’s remarks may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results, operational plans, strategy and market opportunities. These statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act and Section 21E of the Exchange Act and are based on current assumptions and expectations.
Forward-looking statements are neither promises nor guarantees and involve risks and uncertainties that could cause actual results to differ materially. Important factors are discussed in our annual report on Form 10-K for the year ended December 31, 2025, and in subsequent SEC filings, including the quarterly report on Form 10-Q for the quarter ended March 31, 2026. We undertake no obligation to update these statements, except as required by law.
On the call today, we have Dr. Yuping Huang, Chief Executive Officer and Chairman; and Chris Roberts, Chief Financial Officer. The team will provide
HF Foods Group Inc. (HFFG) Q1 2026 Earnings Call May 11, 2026 4:30 PM EDT
Company Participants
Xi Lin – CEO, President & Director Paul McGarry – Chief Financial Officer
Advertisement
Conference Call Participants
Jonathan DeDomenico Aaron Grey – Alliance Global Partners, Research Division Daniel Harriman – Sidoti & Company, LLC William Kirk – ROTH Capital Partners, LLC, Research Division
Advertisement
Presentation
Operator
Greetings, and welcome to HF Foods Group First Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host to turn the call over to Mr. John DeDomenico. Thank you, and over to you, Mr. DeDomenico. You may begin.
Advertisement
Jonathan DeDomenico
Hello, everyone. Welcome to HF Foods Group’s First Quarter 2026 Earnings Conference Call. Joining me on today’s call are Felix Lin, the company’s President and Chief Executive Officer; and Paul McGarry, the company’s Chief Financial Officer.
Before we begin, let me remind everyone that today’s discussion contains forward-looking statements based on management’s current beliefs and expectations about future events, which are subject to several known and unknown risks and uncertainties. If you refer to HF Foods’ earnings release as well as the company’s most recent SEC filings, you will see a discussion of factors that could cause the company’s actual results to differ materially from those expressed or implied by these forward-looking statements. The company undertakes no obligation to update or revise these forward-looking statements in the future.
In these remarks, the company will make several references to non-GAAP financial measures, including adjusted EBITDA and non-GAAP diluted earnings per share. We believe that these measures provide investors with a useful perspective on the underlying growth trends of the business and have included in the earnings release a full reconciliation of non-GAAP financial measures to the most comparable GAAP measures.
Nobel Hygiene Pvt., a maker of hygiene products, is considering an initial public offering in India that could raise as much as $300 million, according to people familiar with the matter.
The Quadria Capital-backed company has held preliminary discussions with investment banks about a potential listing and may appoint advisers in the coming weeks, the people said, asking not to be identified because the information is private.
The proposed IPO could include a mix of fresh share issuance and secondary sales by existing investors, the people said. Deliberations are ongoing, and details such as size and timing could change.
A representative for Nobel Hygiene said the company regularly evaluates strategic and capital market opportunities and engages with external advisers from time to time as part of that process.
Advertisement
Indian firms have raised about $3.1 billion through IPOs so far this year, compared with roughly $22 billion in all of 2025, according to data compiled by Bloomberg.
Live Events
Quadria Capital, one of Asia’s largest healthcare-focused private equity firms, announced in 2021 that it had acquired a significant minority stake in Nobel Hygiene. Founded in 2000 by Kamal Johari, the company manufactures hygiene products tailored to Indian consumers, according to its website.
Regional voters turning to One Nation believe the party is the only one “fighting” for them, coalition politicians say, as the conservative alliance continues to reel from losing a key seat in a by-election.
The Co-op has announced plans to open or refurbish 24 stores in the next few weeks as part of a UK expansion drive in 2026
Alan Jones Press Association Industrial Correspondent
05:00, 12 May 2026
The Co-op is headquartered in Manchester(Image: Getty Images)
The Co-op has announced plans to open or refurbish 24 stores in the next few weeks.
Advertisement
The investment will take the total number of stores launching in the first half of this year to more than 40, stretching from the south coast of England to the Scottish Highlands, including towns, villages and cities in Cumbria, Gloucestershire, Kent, London, the Midlands, Nottinghamshire and Yorkshire.
Kate McCrae, Co-op operations director, said: “We’re investing to create local stores which are more than just a shop, they are a convenient hub contributing to local life and meeting the needs of communities.
“We are moving through 2026 with a strong focus on our members, customers and communities, and a programme designed to enhance Co-op’s presence in high streets and communities across the UK.”
New or transformed Co-op stores opening in Q2 2026
LOS ANGELES — Luka Doncic has reached a significant milestone in his recovery from a Grade 2 left hamstring strain, confirming he has begun running again, but the Lakers superstar remains weeks away from full basketball activity and is highly unlikely to play in the ongoing Western Conference semifinals against the Oklahoma City Thunder.
Luka Doncic
In his first public comments since the injury on April 2, Doncic told reporters he is progressing day by day but emphasized the original medical timeline called for roughly eight weeks of recovery. With the Lakers trailing 2-1 in the series as of Monday, May 11, the Slovenian star’s return appears targeted for late May at the earliest — potentially too late for this round.
“I’m just doing everything I can,” Doncic said. “Every day I’m doing stuff I’m supposed to do. The doctor said eight weeks at the beginning of the first MRI. So I’m just going day by day, and I feel better every day.”
Progress but cautious timeline
Doncic has started running as part of his rehabilitation but has not yet been cleared for full-contact work, scrimmages or 5-on-5 sessions. He traveled to Spain earlier for specialized PRP (platelet-rich plasma) treatment to accelerate healing, a trip that included multiple injections spaced days apart.
Advertisement
Medical experts note that Grade 2 hamstring strains typically require 4-8 weeks, with elite athletes sometimes pushing the lower end under ideal conditions. However, Doncic’s history of lower-body issues and the original eight-week projection from team doctors suggest a conservative approach to avoid re-injury.
Lakers coach JJ Redick and the medical staff continue evaluating him on a week-to-week basis. While Doncic has participated in non-contact shooting and light on-court movement, the critical next steps — controlled contact and game-speed work — remain ahead.
Impact on Lakers’ playoff run
Without Doncic, the Lakers have relied heavily on LeBron James, Austin Reaves and a deep supporting cast. The team has shown resilience but faces an uphill battle against the top-seeded Thunder. James has shouldered extra minutes, yet the drop-off in playmaking and scoring gravity without Doncic is evident.
Advertisement
A potential return in the Western Conference finals would require the Lakers to extend the current series and give Doncic time to ramp up safely. Even then, rust and re-injury risk would loom large against Oklahoma City’s athletic perimeter defenders.
Injury context and prevention
This marks the latest soft-tissue concern for Doncic, who has battled calf and hamstring issues in recent seasons. The April 2 injury occurred in a regular-season game against these same Thunder. Sources say the team is prioritizing long-term health over a rushed return, learning from past setbacks.
Sports medicine specialists stress that premature returns from hamstring strains often lead to longer absences. Doncic’s methodical approach — including specialized treatment abroad — reflects a commitment to proper healing.
Advertisement
Fan and league reaction
Lakers faithful remain hopeful yet realistic, with many expressing frustration over the timing while praising Doncic’s work ethic. National analysts largely agree the current series is a steep challenge without him, though a deep playoff run could still be possible if the supporting cast steps up.
League insiders note the high stakes for a franchise that invested heavily to pair James with Doncic. His absence tests roster depth and coaching adjustments under Redick.
Looking ahead
Advertisement
The focus for Doncic remains steady progression. If the eight-week timeline holds from the early April MRI, he could target late May for a potential return — possibly aligning with a Conference Finals scenario. Any acceleration would depend on pain-free running, strength testing and medical clearance.
For now, the Lakers push forward without their MVP-caliber leader. Doncic’s update offers cautious optimism — he is moving in the right direction — but full basketball activities remain weeks away. The Slovenian star’s determination is clear, yet hamstring recoveries demand patience.
As the Lakers navigate life without him, all eyes remain on Doncic’s rehabilitation. Whether he returns this postseason or begins preparing for next season, his progress will shape Los Angeles’ immediate future and long-term championship aspirations.
You must be logged in to post a comment Login